IVIG, or intravenous immunoglobulin, is a concentrated solution of antibodies pooled from the blood plasma of 10,000 to 15,000 healthy donors, delivered directly into the bloodstream over three to five hours per session. Originally developed for patients with severe immune deficiencies, it has quietly become one of the most versatile treatments in modern medicine, with more than half of all IVIG prescriptions now written for off-label uses ranging from Guillain-Barré syndrome to lupus. For families navigating dementia care, the treatment has drawn attention because of its anti-inflammatory and immune-modulating properties, which researchers continue to study in the context of neurodegenerative disease. The global IVIG market reached approximately $14.4 billion in 2024 and is projected to hit $32.3 billion by 2035, a growth rate of 7.6 percent annually.
That expansion reflects a surge in new FDA approvals, widening clinical applications, and a growing geriatric population that stands to benefit from immune support therapies. But this is not a simple success story. Supply shortages, staggering costs, and real safety considerations make IVIG a treatment that demands careful, informed decision-making. This article breaks down what IVIG actually does, who it helps, what it costs, and what families and patients should know before pursuing it.
Table of Contents
- What Is IVIG Infusion and Why Is This Immune Treatment Getting New Attention?
- How IVIG Works in the Body and Where Its Limits Begin
- The Cost of IVIG Treatment and Who Pays for It
- Weighing the Safety Profile Against the Benefits
- The Global IVIG Shortage and What It Means for Patients
- Emerging Research and Potential Alternatives
- What the Future of IVIG Looks Like
- Conclusion
- Frequently Asked Questions
What Is IVIG Infusion and Why Is This Immune Treatment Getting New Attention?
IVIG works by flooding the body with a broad spectrum of immunoglobulin G antibodies harvested from thousands of donors. This diversity is the point. Because each donor contributes antibodies shaped by their own immune history, the pooled product can modulate immune responses in ways that a single patient’s system cannot. For someone whose immune system is attacking their own nerves, as in chronic inflammatory demyelinating polyneuropathy, or failing to fight infections, as in primary immune deficiency, that infusion of borrowed immunity can be transformative. The treatment has FDA approval for a specific set of conditions: primary immune deficiency, immune thrombocytopenic purpura, B-cell chronic lymphocytic leukemia, Kawasaki disease, multifocal motor neuropathy, CIDP, bone marrow transplant support, and dermatomyositis, which received its approval on July 15, 2021. But physicians also prescribe it for dozens of conditions that fall outside those approvals. Autoimmune hemolytic anemia, certain refractory seizure disorders, and inflammatory conditions that resist other treatments have all been treated with IVIG in clinical practice. The gap between what is approved and what is prescribed is wider with IVIG than with most therapies, which is part of why it generates both enthusiasm and controversy.
What has renewed attention in recent years is the pace of new product approvals. In January 2024, the FDA approved Takeda’s Gammagard Liquid for adults with CIDP. Later that year, Pfizer’s PANZYGA became the only IVIG product with two FDA-approved maintenance dosing options for CIDP, giving neurologists more flexibility in how they manage that condition. In June 2024, Yimmugo 10 percent from Biotest AG was approved for primary immunodeficiency in patients two years and older. And in June 2025, Gammagard Liquid ERC, a new ready-to-use, low-IgA formulation that can be given intravenously or subcutaneously, received FDA approval with a U.S. commercial launch planned for 2026. As of 2024 to 2025, seven immunoglobulin products now carry FDA-approved CIDP indications. That kind of momentum does not happen around a treatment the medical community has lost interest in.
How IVIG Works in the Body and Where Its Limits Begin
The mechanism behind IVIG is more nuanced than simply replacing missing antibodies. In autoimmune conditions, the infused immunoglobulins appear to interfere with the destructive antibodies the patient’s own body is producing. They can block receptors on immune cells, neutralize inflammatory signaling molecules called cytokines, and influence how the complement system tags cells for destruction. In immunodeficiency, the mechanism is more straightforward: the patient lacks sufficient antibodies to fight infection, and IVIG supplies them. However, IVIG is not a cure. For most conditions, its effects are temporary. Patients with CIDP or primary immune deficiency typically require ongoing infusions, sometimes monthly, to maintain clinical benefit.
If treatments stop, symptoms generally return. This creates a long-term commitment that involves repeated infusion sessions, each lasting three to five hours, often at a hospital or specialized infusion center. Some patients can eventually transition to subcutaneous immunoglobulin, which they self-administer at home over shorter sessions, but not all conditions or formulations support that switch. The treatment also does not work for everyone. Response rates vary by condition, and some patients plateau or stop responding over time. Geriatric patients, who represent a growing share of IVIG recipients, face higher risks of serious adverse reactions due to pre-existing conditions like renal insufficiency or cardiovascular disease. For families considering IVIG in the context of neurological decline or brain health, it is worth understanding that while research into its neurological applications continues, the evidence base for conditions like Alzheimer’s disease has not yet produced the results that earlier trials hoped for. This does not mean the science is settled, but it does mean that expectations should be grounded in current data rather than headlines.
The Cost of IVIG Treatment and Who Pays for It
The financial reality of IVIG treatment stops many patients and families in their tracks. Per-gram costs range from $100 to more than $350, depending on the product, the supplier, and the clinical setting. A single treatment course can start at $5,000 to $10,000. For patients requiring four to five infusions per month, as some CIDP and autoimmune patients do, monthly costs can reach approximately $41,796. Over the course of a year, that figure can exceed $500,000, placing IVIG among the most expensive therapies in routine clinical use. insurance coverage varies significantly. Medicare Part B covers the full cost of at-home IVIG for patients with primary immune deficiency disease, with Q1 2026 reimbursement rates effective from January 1 through March 31, 2026.
But coverage for off-label uses is far less predictable. Private insurers frequently require prior authorization, step therapy documentation proving that cheaper treatments have failed, and sometimes peer-to-peer reviews between the prescribing physician and an insurance company medical director. Denials are common and appeals are time-consuming. For a concrete example, consider a 68-year-old patient diagnosed with CIDP who needs monthly IVIG infusions. Even with Medicare or private insurance covering a portion, co-pays and coinsurance can run into thousands of dollars per month. Some specialty pharmacies and manufacturer assistance programs help offset costs, but navigating those programs requires persistence. Families exploring IVIG should ask their neurologist or immunologist to connect them with a financial counselor or patient assistance coordinator before treatment begins, not after the first bill arrives.
Weighing the Safety Profile Against the Benefits
IVIG is considered safe and low-risk relative to its therapeutic potency. Fewer than 5 percent of patients experience moderate or severe side effects. The most common reactions, occurring in 3 to 15 percent of infusions, include headache, nausea, fever, chills, flushing, and fatigue. These are typically transient, resolving within hours of the infusion’s completion, and can often be managed by slowing the infusion rate or pre-medicating with acetaminophen, diphenhydramine, or corticosteroids. The rare serious adverse effects deserve careful attention, however. Occurring in less than 1 percent of cases, these include renal impairment, thrombosis (which can manifest as stroke, heart attack, or pulmonary embolism), aseptic meningitis, hemolytic anemia, and transfusion-related acute lung injury.
The thrombosis risk is worth specific consideration for older adults or anyone with a history of cardiovascular disease, clotting disorders, or prolonged immobility. Patients who are dehydrated or who have impaired kidney function face elevated renal risks, and certain IVIG products with higher sucrose content have been more strongly associated with kidney injury. The tradeoff is straightforward but not simple. For a patient with a life-threatening autoimmune crisis or a primary immune deficiency that leaves them vulnerable to fatal infections, the benefit-to-risk ratio strongly favors treatment. For someone considering IVIG for an off-label indication with weaker evidence, particularly an elderly patient with multiple comorbidities, that calculation changes. Geriatric patients have higher risk of serious adverse reactions, and the decision to start IVIG should involve a candid conversation about what monitoring will look like, what symptoms to watch for between infusions, and at what point the risks might outweigh the benefits.
The Global IVIG Shortage and What It Means for Patients
Supply shortages have become one of the defining challenges of IVIG therapy in the mid-2020s. The European Medicines Agency reports ongoing shortages of immunoglobulin products that are expected to last until at least June 2026. European demand is projected to rise from 60 metric tons in 2019 to 83 metric tons by 2027, and many countries simply cannot keep up. The United Kingdom, France, Greece, Germany, and others have all experienced disruptions in IVIG availability. The root of the problem is plasma supply. The United States supplies approximately 70 percent of the world’s plasma, and many nations lack plasma self-sufficiency.
Collecting plasma is time-intensive and depends on voluntary or compensated donors, and the COVID-19 pandemic disrupted donation patterns in ways that the supply chain has not fully recovered from. Manufacturing IVIG from raw plasma takes months of fractionation, purification, and testing, so even when donation rates improve, the lag before finished product reaches patients is substantial. Some countries are working to build domestic capacity. In early 2025, a new UK-manufactured product called Gamten 10 percent IVIg was introduced, made from plasma donated within the United Kingdom, representing a step toward reducing dependence on imported American plasma. For patients currently receiving IVIG, shortages can mean delayed treatments, switches to unfamiliar products, or rationing that prioritizes the most critically ill. Families should ask their treatment center about contingency plans and whether subcutaneous immunoglobulin might serve as a viable alternative during supply disruptions. Not every patient can make that switch, but for those who can, it offers a buffer against the unpredictability of the current supply landscape.
Emerging Research and Potential Alternatives
Researchers at Rockefeller University have developed a potential IVIG replacement for treating autoimmunity that is reported to be significantly more potent than traditional IVIG. The approach, still in early stages, could eventually address both the efficacy ceiling some patients hit with conventional IVIG and the supply constraints that make the current product vulnerable to shortages. If a synthetic or engineered alternative could deliver the same immune-modulating effects at lower doses and without dependence on thousands of plasma donors per batch, it would represent a fundamental shift in how immune-mediated diseases are managed.
For the dementia and brain health community, these developments matter because neuroinflammation is increasingly recognized as a contributing factor in Alzheimer’s disease, vascular dementia, and other forms of cognitive decline. While IVIG trials for Alzheimer’s have produced mixed results so far, the underlying hypothesis that modulating the immune system could slow neurodegeneration has not been abandoned. More targeted immunoglobulin therapies could eventually reopen that line of investigation with tools better suited to crossing the blood-brain barrier or selectively dampening the inflammatory pathways most relevant to neuronal damage.
What the Future of IVIG Looks Like
The IVIG landscape over the next decade will be shaped by three forces: expanding indications, supply chain restructuring, and the arrival of next-generation alternatives. North America currently dominates the market with 57.09 percent market share, valued at $11.09 billion in 2024, but growth in Asia-Pacific and Europe is accelerating as diagnosis rates for autoimmune and immunodeficiency disorders climb. The approval pipeline remains active, with manufacturers pursuing indications in conditions that have historically relied on off-label prescribing.
For patients and families, the practical takeaway is that IVIG is not going away. It is becoming more available in different formulations, including options like Gammagard Liquid ERC that can be administered subcutaneously at home. But it is also becoming more expensive and more subject to supply constraints as global demand outpaces production. Staying informed, maintaining open communication with prescribing physicians, and understanding both the promise and the limitations of IVIG will matter more in the coming years than it ever has before.
Conclusion
IVIG remains one of the most powerful and versatile immunological treatments available, with a safety profile that holds up well for the vast majority of patients. Its recent wave of FDA approvals, including new CIDP and primary immunodeficiency indications through 2024 and 2025, reflects growing clinical confidence and expanding options. But the picture is complicated by costs that can reach tens of thousands of dollars per month, a global supply chain strained by demand that outstrips plasma collection, and a shortage timeline that extends into 2026 and beyond.
For families involved in dementia care or monitoring brain health in aging loved ones, IVIG is worth understanding even if it is not currently indicated for cognitive conditions. The immune system’s role in neurodegeneration is an active area of research, and the tools being developed today, from more potent immunoglobulin alternatives to subcutaneous formulations that patients can use at home, may become directly relevant in the years ahead. Talk to your neurologist or immunologist if you have questions about whether IVIG has a role in your family’s care plan, and do not let the complexity of the treatment discourage you from asking.
Frequently Asked Questions
How long does an IVIG infusion session take?
A typical IVIG infusion takes 3 to 5 hours to complete. The rate is usually started slowly and gradually increased to reduce the risk of side effects. Some patients may need longer sessions if they are sensitive to faster infusion rates.
Does Medicare cover IVIG treatment?
Medicare Part B covers the full cost of at-home IVIG for patients with primary immune deficiency disease. Coverage for other conditions depends on the specific diagnosis, whether the use is FDA-approved or off-label, and individual plan policies. Prior authorization is often required.
What are the most common side effects of IVIG?
The most common side effects, occurring in 3 to 15 percent of infusions, include headache, nausea, fever, chills, flushing, and fatigue. These are usually mild and resolve shortly after the infusion ends. Serious adverse effects like thrombosis or renal impairment occur in less than 1 percent of patients.
Why is there an IVIG shortage?
The United States supplies roughly 70 percent of the world’s plasma, and many countries lack self-sufficiency in plasma collection. Rising global demand, projected to increase from 60 to 83 metric tons in Europe alone by 2027, has outpaced supply. The European Medicines Agency expects shortages to continue until at least June 2026.
Can IVIG be given at home?
Some IVIG products, including the newly approved Gammagard Liquid ERC, can be administered subcutaneously at home rather than intravenously at an infusion center. However, not all patients or conditions are appropriate for home administration, and the decision should be made in consultation with the prescribing physician.
Is IVIG used to treat dementia or Alzheimer’s disease?
IVIG is not currently FDA-approved for Alzheimer’s disease or other forms of dementia. Clinical trials exploring its use in Alzheimer’s have produced mixed results. However, research into neuroinflammation and immune modulation in neurodegenerative disease continues, and next-generation immunoglobulin therapies may eventually revisit this application.
